MELD Score Exceptions
MELD score exceptions are granted to patients whose mortality risk is not accurately reflected by their laboratory MELD score, and these exceptions fall into three main categories: manifestations of cirrhosis (including hepatopulmonary syndrome, portopulmonary hypertension, refractory ascites, and recurrent bleeding/encephalopathy), miscellaneous liver diseases (including Budd-Chiari syndrome, familial amyloidotic polyneuropathy, and polycystic liver disease), and malignancies (primarily hepatocellular carcinoma and cholangiocarcinoma). 1
Recognized Exception Categories
The EASL guidelines clearly delineate that patients with liver diseases requiring transplantation whose severity is not captured by MELD should receive different priority through expert assessment 1. The structured exception framework includes:
Manifestations of Cirrhosis
- Refractory ascites - fluid accumulation unresponsive to medical therapy
- Recurrent gastrointestinal bleeding - despite optimal management
- Recurrent or chronic encephalopathy - persistent neurological dysfunction
- Hepatopulmonary syndrome - pulmonary vascular dilation causing hypoxemia
- Portopulmonary hypertension - pulmonary arterial hypertension in portal hypertension setting
- Intractable pruritus - resistant to all medical therapies 1
Miscellaneous Liver Diseases
- Budd-Chiari syndrome
- Familial amyloidotic polyneuropathy
- Cystic fibrosis
- Hereditary hemorrhagic telangiectasia
- Polycystic liver disease
- Primary oxaluria
- Recurrent cholangitis
- Uncommon metabolic diseases 1
Malignancies
- Hepatocellular carcinoma (HCC) - the most common exception
- Cholangiocarcinoma - under specific protocols
- Uncommon liver tumors 1
Priority Stratification System
The consensus-based allocation model stratifies exceptions into four priority levels 2:
Priority 1 (P1) - 30 points, Macro area allocation:
- Rendu-Osler-Weber syndrome
- Young adult hepatoblastoma
- Kasabach-Merritt syndrome
- Late "acute" retransplant
Priority 2 (P2) - 25 points + 1/month, Regional allocation:
- Hepatopulmonary syndrome
- Portopulmonary hypertension (with specific hemodynamic criteria)
- Late "chronic" retransplant
- Refractory hydrothorax
- Hepatorenal syndrome
- Previous severe infections
Priority 3 (P3) - 20 points + 1 every 2 months, Regional allocation:
- Refractory ascites
- Familial amyloidotic polyneuropathy
- Wilson's disease with initial neurological symptoms and well-compensated cirrhosis
- Neuroendocrine tumor metastases
- Hemangioendothelioma
Priority 4 (P4) - 15 points + 1 every 2 months, Regional allocation:
- Complicated adenomatosis
- Polycystic disease
- Primary sclerosing cholangitis or primary biliary cirrhosis with intractable pruritus 2
HCC-Specific Exception Criteria
HCC represents a unique exception requiring standardized extra points based on tumor size, number of nodules, AFP levels, waiting time, and response to downstaging procedures 1. The allocation must account for dropout risk while maintaining transplant utility. Patients with transplantable HCC after downstaging or showing partial response to bridge therapy receive higher priority due to increased dropout risk 2.
Critical Clinical Considerations
Timing Thresholds
- List patients when MELD ≥15, as survival below this threshold is better without transplantation 1
- For MELD >30, carefully assess perioperative mortality and morbidity risk 1
- MELD scores >35 predict post-transplant mortality 1
Portopulmonary Hypertension Updates
Recent 2021 modifications allow exception approval for either: (1) mPAP <35 mmHg AND PVR <400 dynes-s-cm⁻⁵ (<5 Wood units), OR (2) mPAP 35-45 mmHg AND PVR <240 dynes-s-cm⁻⁵ (<3 Wood units) post-treatment 3. This recognizes that PVR, not mPAP alone, better predicts outcomes.
Common Pitfalls
- Regional variation exists in non-recognized exceptional diagnosis (non-RED) exception approval, with approval rates increasing from <50% in 2002 to nearly 75% in 2010 4
- Patients with approved exceptions have significantly higher transplant rates (68.3% vs 53.4%) and lower mortality (10.4% vs 16.2%) compared to those without exceptions 4
- Exception criteria must balance transparency, equity, justice, and utility in the context of organ scarcity 5
Multidisciplinary Decision-Making
Final decisions require collaboration among transplant hepatologists, surgeons, and specialists accounting for all comorbidities within each expert center 1. Exception applications should be reviewed by regional boards with expertise in assessing disease progression patterns and treatment responses.